News, views and contacts from the global Drugdevelopment industry
22 June 2017
Industry News

New Phase I/II trial indicates positive outcome for Astellas' cancer drug
US researchers at the University of Pennsylvania’s (Penn) Perelman School of Medicine and Abramson Cancer Centre have reported positive data from a Phase I/II clinical trial of Astellas Pharmaceuticals’ new drug gilteritinib in patients with acute myeloid leukaemia (AML).

Immune Pharma starts enrolment in Phase I/II trial of Ceplene for CMML
Immune Pharmaceuticals has started patient recruitment for Phase I/II clinical trial of Ceplene (histamine dihydrochloride) to treat chronic myelomonocytic leukaemia (CMML) patients. 

InDex initiates enrolment for Phase IIb trial of cobitolimod to treat ulcerative colitis
Sweden-based InDex Pharmaceuticals has started patient enrolment in Phase IIb CONDUCT clinical trial of cobitolimod for treatment of patients with ulcerative colitis.

Hansa Medical begins IdeS dosing in Phase II trial for anti-GBM antibody disease
Swedish biopharmaceutical firm Hansa Medical has begun dosing patients in its Phase II clinical trial of drug candidate IgG degrading enzyme of Streptococcus pyogenes (IdeS), to treat patients with severe anti-GBM antibody disease / Goodpasture’s disease.

Press Releases

Breaking Down Complex Generics
Pharmaceutical consulting and generic drug professionals: What is your hedge against the increasingly crowded traditional drug markets?

Pharmatest Ltd Establishes New US-Based Subsidiary Pharmatest LLC
Pharmatest Services LLC is newly established US based contract research organization (CRO) operating in Massachusetts. It offers preclinical efficacy services in oncology and skeletal diseases. The company is a fully owned subsidiary of Pharmatest Services Ltd based in Finland.

Upcoming Events Malvern
Malvern has announced a number of webinars that will take place throughout June.

Explaining Biosimilars
Pharmaceutical consulting and generic drug professionals: What is your hedge against the financial risk associated with increasingly crowded traditional drug markets?

Gamlen Instruments Announces New Company Name
Gamlen Tableting has announced it is changing its trading name from 'Gamlen Tableting' to 'Gamlen Instruments' to acknowledge the company's established global presence as a leader in benchtop powder compaction instrumentation.

White Papers

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture
Systag Systems presents ePAT, a cost-effective device for automation in the laboratory....

Paradigm Shift Regarding API and Formulation Components
This whitepaper will provide an introduction to high-purity carbohydrates often used for applications such as stabilisation, modulation, and cryopreservation, comparing the old paradigm...

Characterisation Information of Critical Excipients for Sourcing Critical Raw Materials
The increasing complexity of large molecule and cell-based therapeutics calls for an evolution in our understanding of the impurity and functional contributions of each formulation...

Application: Operating Reactor Systems for Process Research and Development
In this case study, three reactor systems (FlexyCUBE 70ml, FlexyPAT 2l, and ChemTeacktor 25l) are operated on the same PC using application software...

Benefits of Trehalose
Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of...

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.